Formosa Pharmaceuticals, Inc. announced that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics. The foundation of the collaboration lies in the combination of Formosa's APNT™ formulation platform with Eyenovia's Optejet® delivery system. Eyenovia's Optejet® delivery platform for ocular therapeutics utilizes Microdose Array Print (MAP™) technology to deliver 6-8 microliters of drug product, consistent with the capacity of the tear film of the eye.

At less than 20% volume of that delivered by conventional eyedroppers, Optejet® reduces the risk of overdosing and unnecessary drug exposure. Furthermore, the Optejet® action is both rapid and gentle, ensuring efficient and comfortable delivery to the ocular surface. Formosa's proprietary APNT™ formulation platform improves dissolution and bioavailability of active pharmaceutical ingredients via a mild and efficient particle size reduction technique optimized for topical, oral, or inhaler administration routes.

Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues.